Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Moradi G, Mohamadi Bolbanabad A, Ahmadi S, Aghaei A, Bahrami F, Veysi A, Nasiri Kalmarzi R, Shokri A, Ghaderi E, Mohsenpour B, Mohammadi A. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study. Int Immunopharmacol 2021;98:107893. [PMID: 34174700 PMCID: PMC8206627 DOI: 10.1016/j.intimp.2021.107893] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 06/12/2021] [Accepted: 06/12/2021] [Indexed: 12/30/2022]

For:	Moradi G, Mohamadi Bolbanabad A, Ahmadi S, Aghaei A, Bahrami F, Veysi A, Nasiri Kalmarzi R, Shokri A, Ghaderi E, Mohsenpour B, Mohammadi A. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study. Int Immunopharmacol 2021;98:107893. [PMID: 34174700 PMCID: PMC8206627 DOI: 10.1016/j.intimp.2021.107893] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 06/12/2021] [Accepted: 06/12/2021] [Indexed: 12/30/2022]

Number

Cited by Other Article(s)

Siles Alvarado N, Schuler M, Maguire C, Amengor DA, Nguyen AW, Wilen RE, Rogers J, Bazzi S, Caslin B, DiPasquale C, Abigania M, Olson E, Creaturo J, Hurley K, Triplett TA, Rousseau JF, Strakowski SM, Wylie D, Maynard JA, Ehrlich LIR, Melamed E. SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics. COMMUNICATIONS MEDICINE 2025;5:149. [PMID: 40316665 PMCID: PMC12048490 DOI: 10.1038/s43856-025-00828-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Accepted: 03/28/2025] [Indexed: 05/04/2025] Open

Abstract

BACKGROUND

Defining the kinetics of SARS-CoV-2 antibody responses is critical for informing the management of reinfections, vaccinations, and therapeutics of Coronavirus disease 2019 (COVID-19).

METHODS

Using four antibody assays, we evaluated antibody titers against SARS-CoV-2 nucleocapsid (N), spike (S), and receptor binding domain (RBD) in 98 convalescent participants with varying COVID-19 disease severities (asymptomatic, mild, moderate or severe) at 1, 3, 6, and 12-months post-SARS-CoV-2-positive PCR and in 17 non-vaccinated, non-infected controls.

RESULTS

Increasing acute COVID-19 disease severity correlates with higher anti-N and anti-RBD titers throughout 12 months post-infection. Anti-N and anti-RBD titers decline over time in all participants, except for increased anti-RBD titers post-vaccination, with hospitalized participants exhibiting faster decay rates. Less than 50% of participants retain anti-N titers above controls at 12 months, with non-hospitalized participants falling below controls sooner. Nearly all participants maintain anti-RBD titers above controls for 12 months, suggesting long-term protection against severe reinfections. Nonetheless, by 6 months, few participants retain >50% of their initial 1-month anti-N or anti-RBD titers. Notably, vaccine-induced anti-RBD titers are higher in non-hospitalized participants. Lastly, early convalescent titers correlate with age but not with Post-Acute Sequelae of SARS-CoV-2 infection (PASC) status or steroid use.

CONCLUSION

Hospitalized participants initially develop higher anti-SARS-CoV-2 antibody titers that decline faster relative to non-hospitalized participants. While anti-N titers fall below control levels in some participants, anti-RBD titers remain above controls over 12 months, demonstrating long-lived antibody responses known to protect against severe disease. These findings advance our understanding of COVID-19 antibody dynamics.

Collapse

Affiliation(s)

Nadia Siles Alvarado Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
Maisey Schuler Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
Cole Maguire Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
Dzifa A Amengor Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA
Annalee W Nguyen Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA
Rebecca E Wilen Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA
Jacob Rogers Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
Sam Bazzi Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
Blaine Caslin Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
Christopher DiPasquale Babson Diagnostics, Austin, TX, USA
Melissa Abigania Babson Diagnostics, Austin, TX, USA
Eric Olson Babson Diagnostics, Austin, TX, USA
Janelle Creaturo Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
Kerin Hurley Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA Dell Seton Medical Center at The University of Texas, Austin, TX, USA
Todd A Triplett Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA Department of Immunotherapeutics & Biotechnology, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA
Justin F Rousseau Department of Population Health, Dell Medical School, The University of Texas at Austin, Austin, TX, USA Biostatistics and Clinical Informatics Section, Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA
Stephen M Strakowski Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA Department of Psychiatry, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
Dennis Wylie Center for Biomedical Research Support, The University of Texas at Austin, Austin, TX, USA
Jennifer A Maynard Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA
Lauren I R Ehrlich Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA. Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
Esther Melamed Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.

Collapse

Liu X, Xin Y, Zhang L, Wu Y, Jing S, Dai Z, Ren T, Liu X, Fu J, Chen X, Xiao W, Wang H, Huang Y, Wang W, Gu X, Ma L, Zhang S, Yu Y, Li L, Gao T, Zhao T, Qu Y, Liu X, Su X, Qiao Y. Uptake and hesitancy of the second booster dose of COVID-19 vaccine among the general population in China after the surge period of the COVID-19 pandemic: a large-scale national study. BMC Public Health 2025;25:503. [PMID: 39920639 PMCID: PMC11803999 DOI: 10.1186/s12889-025-21691-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2024] [Accepted: 01/30/2025] [Indexed: 02/09/2025] Open

Abstract

BACKGROUND

Although the second booster dose of COVID-19 vaccines is available, vaccine hesitancy among the public may have peaked due to the surge in infections caused by the Omicron variant. To improve coverage of the second booster dose, it is crucial to investigate the prevalence of vaccine hesitancy among the general population during this period and explore the reasons for this phenomenon.

METHODS

A cross-sectional survey was conducted between January 5 to February 9, 2023. Variables including sociodemographics, mental health, COVID-19 infection status, COVID-19 vaccination status, and vaccine hesitancy were collected. Univariate and multivariate logistic regression analysis were performed to identify factors associated with the hesitancy of the second booster dose of COVID-19 vaccine among the general population.

RESULTS

Among the 10,623 participants, the uptake rate of the second booster dose was 4.3%. Among those who did not receive the second booster dose, 43.6% expressed vaccine hesitancy. The highest hesitancy rate was observed among participants who had not completed primary immunization (71.4%), followed by those with chronic diseases (48.6%) and those aged 60 and above (33.2%). The COVID-19 vaccine hesitancy was higher among females, participants with high incomes, those with a history of COVID-19 infection, those with depressive symptoms and post-traumatic stress disorder, and those with adverse events after COVID-19 vaccination. Conversely, lower hesitancy was observed among students, participants aged 60 and above, those from southern China, and those with higher level of perceived social support.

CONCLUSIONS

COVID-19 vaccine hesitancy remains prevalent among the general population in China after the surge period of the pandemic. Crucial steps, such as raising public awareness of the benefits and potential side effects of regular COVID-19 vaccination, ensuring timely monitoring and disclosure of pandemic information, and implementing targeted measures to improve social support and mental health, should be taken. These efforts will be instrumental in reducing vaccine hesitancy, advancing vaccination campaigns, and effectively preparing for the potential future outbreaks.

Collapse

Affiliation(s)

Xin Liu School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
You Xin School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Ling Zhang School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Yijin Wu School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Shu Jing School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Zhenwei Dai Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
Tianrui Ren School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Xiaoyang Liu School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Jiaqi Fu School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Xu Chen School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Weijun Xiao School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Hao Wang School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Yiman Huang School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Wenjun Wang School of Nursing, Jining Medical University, Jining, China
Xiaofen Gu Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China
Li Ma Public Health School, Dalian Medical University, Dalian, China
Shaokai Zhang Henan Cancer Hospital, Affiliate Cancer Hospital of Zhengzhou University, Zhengzhou, China
Yanqin Yu The First Affiliated Hospital of Baotou Medical College, Baotou, China
Li Li Department of Clinical Research, the First Affiliated Hospital of Jinan University, Guangzhou, China
Tianzuo Gao University of Rochester, Rochester, USA
Tianyou Zhao Trinity College, Hartford, USA
Yimin Qu School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Xinyan Liu Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xiaoyou Su School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Youlin Qiao School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Department of Epidemiology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Collapse

Moradi G, Piroozi B, Khayyati F, Moradpour F, Safari H, Mohamadi Bolbanabad A, Fattahi H, Younesi F, Ebrazeh A, Shokri A. The effect of COVID-19 on utilization of chronic diseases services. Chronic Illn 2024;20:309-319. [PMID: 37488977 PMCID: PMC10372501 DOI: 10.1177/17423953231178168] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2022] [Accepted: 05/08/2023] [Indexed: 07/26/2023]

Stern D, Meyer TC, Treindl F, Mages HW, Krüger M, Skiba M, Krüger JP, Zobel CM, Schreiner M, Grossegesse M, Rinner T, Peine C, Stoliaroff-Pépin A, Harder T, Hofmann N, Michel J, Nitsche A, Stahlberg S, Kneuer A, Sandoni A, Kubisch U, Schlaud M, Mankertz A, Schwarz T, Corman VM, Müller MA, Drosten C, de la Rosa K, Schaade L, Dorner MB, Dorner BG. A bead-based multiplex assay covering all coronaviruses pathogenic for humans for sensitive and specific surveillance of SARS-CoV-2 humoral immunity. Sci Rep 2023;13:21846. [PMID: 38071261 PMCID: PMC10710470 DOI: 10.1038/s41598-023-48581-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Accepted: 11/28/2023] [Indexed: 12/18/2023] Open

Affiliation(s)

Daniel Stern Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany.
Tanja C Meyer Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Fridolin Treindl Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Hans Werner Mages Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Maren Krüger Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Martin Skiba Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Jan Philipp Krüger Department of Microbiology and Hospital Hygiene, Bundeswehr Hospital Berlin, Berlin, Germany
Christian M Zobel Department of Internal Medicine, Bundeswehr Hospital Berlin, Berlin, Germany
Maximilian Schreiner Department of Internal Medicine, Bundeswehr Hospital Berlin, Berlin, Germany
Marica Grossegesse Highly Pathogenic Viruses (ZBS 1), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Thomas Rinner Highly Pathogenic Viruses (ZBS 1), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Caroline Peine Immunization Unit (FG 33), Department for Infectious Disease Epidemiology, Robert Koch Institute, 13353, Berlin, Germany
Anna Stoliaroff-Pépin Immunization Unit (FG 33), Department for Infectious Disease Epidemiology, Robert Koch Institute, 13353, Berlin, Germany
Thomas Harder Immunization Unit (FG 33), Department for Infectious Disease Epidemiology, Robert Koch Institute, 13353, Berlin, Germany
Natalie Hofmann Highly Pathogenic Viruses (ZBS 1), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Janine Michel Highly Pathogenic Viruses (ZBS 1), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Andreas Nitsche Highly Pathogenic Viruses (ZBS 1), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Silke Stahlberg Central Epidemiological Laboratory (FG 22), Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101, Berlin, Germany
Antje Kneuer Central Epidemiological Laboratory (FG 22), Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101, Berlin, Germany
Anna Sandoni Central Epidemiological Laboratory (FG 22), Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101, Berlin, Germany
Ulrike Kubisch Central Epidemiological Laboratory (FG 22), Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101, Berlin, Germany
Martin Schlaud Central Epidemiological Laboratory (FG 22), Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101, Berlin, Germany
Annette Mankertz Measles, Mumps, Rubella, and Viruses Affecting Immunocompromised Patients (FG 12), Robert Koch Institute, 13353, Berlin, Germany
Tatjana Schwarz Institute of Virology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany
Victor M Corman Institute of Virology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany Corporate Member, Freie Universität Berlin, 10117, Berlin, Germany Corporate Member, Humboldt-Universität zu Berlin, 14195, Berlin, Germany
Marcel A Müller Institute of Virology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany
Christian Drosten Institute of Virology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany
Kathrin de la Rosa Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125, Berlin, Germany Berlin Institute of Health (BIH), Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany
Lars Schaade Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Martin B Dorner Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany
Brigitte G Dorner Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353, Berlin, Germany.

Collapse

Siles N, Schuler M, Maguire C, Amengor D, Nguyen A, Wilen R, Rogers J, Bazzi S, Caslin B, DiPasquale C, Abigania M, Olson E, Creaturo J, Hurley K, Triplett TA, Rousseau JF, Strakowski SM, Wylie D, Maynard J, Ehrlich LIR, Melamed E. SARS-CoV-2 Humoral Immune Responses in Convalescent Individuals Over 12 Months Reveal Severity-Dependent Antibody Dynamics. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2023:2023.12.05.23299462. [PMID: 38106077 PMCID: PMC10723498 DOI: 10.1101/2023.12.05.23299462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2023]

Abstract

Background

Understanding the kinetics and longevity of antibody responses to SARS-CoV-2 is critical to informing strategies toward reducing Coronavirus disease 2019 (COVID-19) reinfections, and improving vaccination and therapy approaches.

Methods

We evaluated antibody titers against SARS-CoV-2 nucleocapsid (N), spike (S), and receptor binding domain (RBD) of spike in 98 convalescent participants who experienced asymptomatic, mild, moderate or severe COVID-19 disease and in 17 non-vaccinated, non-infected controls, using four different antibody assays. Participants were sampled longitudinally at 1, 3, 6, and 12 months post-SARS-CoV-2 positive PCR test.

Findings

Increasing acute COVID-19 disease severity correlated with higher anti-N and anti-RBD antibody titers throughout 12 months post-infection. Anti-N and anti-RBD titers declined over time in all participants, with the exception of increased anti-RBD titers post-vaccination, and the decay rates were faster in hospitalized compared to non-hospitalized participants. <50% of participants retained anti-N titers above control levels at 12 months, with non-hospitalized participants falling below control levels sooner. Nearly all hospitalized and non-hospitalized participants maintained anti-RBD titers above controls for up to 12 months, suggesting longevity of protection against severe reinfections. Nonetheless, by 6 months, few participants retained >50% of their 1-month anti-N or anti-RBD titers. Vaccine-induced increases in anti-RBD titers were greater in non-hospitalized relative to hospitalized participants. Early convalescent antibody titers correlated with age, but no association was observed between Post-Acute Sequelae of SARS-CoV-2 infection (PASC) status or acute steroid treatment and convalescent antibody titers.

Interpretation

Hospitalized participants developed higher anti-SARS-CoV-2 antibody titers relative to non-hospitalized participants, a difference that persisted throughout 12 months, despite the faster decline in titers in hospitalized participants. In both groups, while anti-N titers fell below control levels for at least half of the participants, anti-RBD titers remained above control levels for almost all participants over 12 months, demonstrating generation of long-lived antibody responses known to correlate with protection from severe disease across COVID-19 severities. Overall, our findings contribute to the evolving understanding of COVID-19 antibody dynamics.

Funding

Austin Public Health, NIAAA, Babson Diagnostics, Dell Medical School Startup.

Collapse

Affiliation(s)

Nadia Siles Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas
Maisey Schuler Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas
Cole Maguire Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas
Dzifa Amengor Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas
Annalee Nguyen Department of Chemical Engineering, University of Texas at Austin, Austin, Texas
Rebecca Wilen Department of Chemical Engineering, University of Texas at Austin, Austin, Texas
Jacob Rogers Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas
Sam Bazzi Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas
Blaine Caslin Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas
Christopher DiPasquale Babson Diagnostics, Austin, Texas
Melissa Abigania Babson Diagnostics, Austin, Texas
Eric Olson Babson Diagnostics, Austin, Texas
Janelle Creaturo Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas
Kerin Hurley Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas; Dell Seton Medical Center at the University of Texas, Austin, Texas
Todd A Triplett Department of Oncology Dell Medical School, University of Texas at Austin, Austin, Texas; Department of Immunotherapeutics & Biotechnology, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA
Justin F Rousseau Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas; Department of Population Health, Dell Medical School, University of Texas at Austin, Austin, Texas
Stephen M Strakowski Department of Psychiatry, Indiana University School of Medicine, Indianapolis; Department of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, Texas
Dennis Wylie Center for Biomedical Research Support, University of Texas at Austin, Austin Texas
Jennifer Maynard Department of Chemical Engineering, University of Texas at Austin, Austin, Texas
Lauren I R Ehrlich Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas
Esther Melamed Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas

Collapse

El Abdellati K, Lucas A, Perron H, Tamouza R, Nkam I, Richard JR, Fried S, Barau C, Djonouma N, Pinot A, Fourati S, Rodriguez C, Coppens V, Meyer U, Morrens M, De Picker L, Leboyer M. High unrecognized SARS-CoV-2 exposure of newly admitted and hospitalized psychiatric patients. Brain Behav Immun 2023;114:500-510. [PMID: 37741299 DOI: 10.1016/j.bbi.2023.09.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 08/28/2023] [Accepted: 09/16/2023] [Indexed: 09/25/2023] Open

Abstract

BACKGROUND

Patients with pre-existing mental disorders are at higher risk for SARS-CoV-2 infection and adverse outcomes, and severe mental illness, including mood and psychosis spectrum disorders, is associated with increased mortality risk. Despite their increased risk profile, patients with severe mental illness have been understudied during the pandemic, with limited estimates of exposure in inpatient settings.

OBJECTIVE

The aim of this study was to describe the SARS-CoV-2 seroprevalence and antibody titers, and pro-inflammatory cytokine concentrations of newly admitted or hospitalized psychiatric inpatients without known history of COVID-19 infection, using robust quantitative multi-antigen assessments, and compare patients' exposure to that of hospital staff.

METHODS

This multi-centric, cross-sectional study compared SARS-CoV-2 seroprevalence and titers of 285 patients (University Psychiatric Centre Duffel [UPCD] N = 194; Assistance-Publique-Hopitaux de Paris [AP-HP] N = 91), and 192 hospital caregivers (UPCD N = 130; AP-HP N = 62) at two large psychiatric care facilities between January 1st and the May 30th 2021. Serum levels of SARS-CoV-2 antibodies against Spike proteins (full length), spike subunit 1 (S1), spike subunit 2 (S2), spike subunit 1 receptor binding domain (S1-RBD) and Nucleocapsid proteins were quantitatively determined using an advanced capillary Western Blot technique. To assess the robustness of the between-group seroprevalence differences, we performed sensitivity analyses with stringent cut-offs for seropositivity. We also assessed peripheral concentrations of IL-6, IL-8 and TNF-a using ELLA assays. Secondary analyses included comparisons of SARS-CoV-2 seroprevalence and titers between patient diagnostic subgroups, and between newly admitted (hospitalization ≤ 7 days) and hospitalized patients (hospitalization > 7 days) and correlations between serological and cytokines.

RESULTS

Patients had a significantly higher SARS-CoV-2 seroprevalence (67.85 % [95% CI 62.20-73.02]) than hospital caregivers (27.08% [95% CI 21.29-33.77]), and had significantly higher global SARS-CoV-2 titers (F = 29.40, df = 2, p < 0.0001). Moreover, patients had a 2.51-fold (95% CI 1.95-3.20) higher SARS-CoV-2 exposure risk compared to hospital caregivers (Fisher's exact test, P < 0.0001). No difference was found in SARS-CoV-2 seroprevalence and titers between patient subgroups. Patients could be differentiated most accurately from hospital caregivers by their higher Spike protein titers (OR 136.54 [95% CI 43.08-481.98], P < 0.0001), lower S1 (OR 0.06 [95% CI 0.02-0.15], P < 0.0001) titers and higher IL-6 (OR 3.41 [95% CI 1.73-7.24], P < 0.0001) and TNF-α (OR 34.29 [95% CI 5.00-258.87], P < 0.0001) and lower titers of IL-8 (OR 0.13 [95% CI 0.05-0.30], P < 0.0001). Seropositive patients had significantly higher SARS-COV-2 antibody titers compared to seropositive hospital caregivers (F = 19.53, df = 2, P < 0.0001), while titers were not different in seronegative individuals. Pro-inflammatory cytokine concentrations were not associated with serological status.

CONCLUSION

Our work demonstrated a very high unrecognized exposure to SARS-CoV-2 among newly admitted and hospitalized psychiatric inpatients, which is cause for concern in the context of highly robust evidence of adverse outcomes following COVID-19 in psychiatric patients. Attention should be directed toward monitoring and mitigating exposure to infectious agents within psychiatric hospitals.

Collapse

Affiliation(s)

K El Abdellati Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium; Scientific Initiative of Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Centre Duffel, Duffel, Belgium.
A Lucas Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), plateau We-Met, Inserm UMR1297 and Université Paul Sabatier, Toulouse, France
H Perron GeNeuro, Plan-les-Ouates, Geneva, Switzerland; Geneuro-Innovation, Lyon, France
R Tamouza INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University, Fondation FondaMental, 94010 Créteil, France; ECNP Immuno-NeuroPsychiatry Network
I Nkam INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University, Fondation FondaMental, 94010 Créteil, France
J-R Richard INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University, Fondation FondaMental, 94010 Créteil, France
S Fried Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), plateau We-Met, Inserm UMR1297 and Université Paul Sabatier, Toulouse, France
C Barau Plateforme de resources biologiques, Hôpital Universitaire Henri Mondor, Université Paris Est Créteil, Créteil, France
N Djonouma Département Hospitalo-Universitaire de psychiatrie et d'addictologie des hopitaux Henri Mondor, Créteil, France
A Pinot INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University, Fondation FondaMental, 94010 Créteil, France
S Fourati Department of Virology, INSERM U955, Team « Viruses, Hepatology, Cancer », Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
C Rodriguez Department of Virology, INSERM U955, Team « Viruses, Hepatology, Cancer », Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
V Coppens Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium; Scientific Initiative of Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Centre Duffel, Duffel, Belgium
U Meyer ECNP Immuno-NeuroPsychiatry Network; Institute of Pharmacology and Toxicology, University of Zürich-Vetsuisse, Zürich, Switzerland; Neuroscience Center Zürich, Zürich, Switzerland
M Morrens Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium; Scientific Initiative of Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Centre Duffel, Duffel, Belgium
L De Picker Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium; Scientific Initiative of Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Centre Duffel, Duffel, Belgium; ECNP Immuno-NeuroPsychiatry Network
M Leboyer INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University, Fondation FondaMental, 94010 Créteil, France; ECNP Immuno-NeuroPsychiatry Network

Collapse

Barrios MH, Nicholson S, Bull RA, Martinello M, Rawlinson W, Mina M, Post JJ, Hudson B, Gilroy N, Lloyd AR, Konecny P, Mordant F, Catton M, Subbarao K, Caly L, Druce J, Netter HJ. Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19. Microorganisms 2023;11:1985. [PMID: 37630545 PMCID: PMC10458948 DOI: 10.3390/microorganisms11081985] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2023] [Revised: 07/10/2023] [Accepted: 07/21/2023] [Indexed: 08/27/2023] Open

Abstract

Serological diagnostic assays are essential tools for determining an individual's protection against viruses like SARS-CoV-2, tracking the spread of the virus in the community, and evaluating population immunity. To assess the diversity and quality of the anti-SARS-CoV-2 antibody response, we have compared the antibody profiles of people with mild, moderate, and severe COVID-19 using a dot blot assay. The test targeted the four major structural proteins of SARS-CoV-2, namely the nucleocapsid (N), spike (S) protein domains S1 and S2, and receptor-binding domain (RBD). Serum samples were collected from 63 participants at various time points for up to 300 days after disease onset. The dot blot assay revealed patient-specific differences in the anti-SARS-CoV-2 antibody profiles. Out of the 63 participants with confirmed SARS-CoV-2 infections and clinical COVID-19, 35/63 participants exhibited diverse and robust responses against the tested antigens, while 14/63 participants displayed either limited responses to a subset of antigens or no detectable antibody response to any of the antigens. Anti-N-specific antibody levels decreased within 300 days after disease onset, whereas anti-S-specific antibodies persisted. The dynamics of the antibody response did not change during the test period, indicating stable antibody profiles. Among the participants, 28/63 patients with restricted anti-S antibody profiles or undetectable anti-S antibody levels in the dot blot assay also exhibited weak neutralization activity, as measured by a surrogate virus neutralization test (sVNT) and a microneutralization test. These results indicate that in some cases, natural infections do not lead to the production of neutralizing antibodies. Furthermore, the study revealed significant serological variability among patients, regardless of the severity of their COVID-19 illness. These differences need to be carefully considered when evaluating the protective antibody status of individuals who have experienced primary SARS-CoV-2 infections.

Collapse

Affiliation(s)

Marilou H. Barrios Victorian Infectious Diseases Reference Laboratory (VIDRL), The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia; (M.H.B.); (S.N.); (M.C.); (L.C.); (J.D.) Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; (F.M.); (K.S.)
Suellen Nicholson Victorian Infectious Diseases Reference Laboratory (VIDRL), The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia; (M.H.B.); (S.N.); (M.C.); (L.C.); (J.D.) Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; (F.M.); (K.S.)
Rowena A. Bull The Kirby Institute, University of New South Wales (UNSW), Sydney, NSW 2052, Australia; (R.A.B.); (M.M.); (A.R.L.) School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, NSW 2052, Australia;
Marianne Martinello The Kirby Institute, University of New South Wales (UNSW), Sydney, NSW 2052, Australia; (R.A.B.); (M.M.); (A.R.L.)
William Rawlinson School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, NSW 2052, Australia; Serology and Virology Division, Department of Microbiology, New South Wales Health Pathology, Randwick, Sydney, NSW 2031, Australia Prince of Wales Hospital, Sydney, NSW 2031, Australia;
Michael Mina Northern Beaches Hospital, Frenchs Forest, NSW 2086, Australia;
Jeffrey J. Post Prince of Wales Hospital, Sydney, NSW 2031, Australia; School of Clinical Medicine, University of New South Wales (UNSW), Sydney, NSW 2052, Australia;
Bernard Hudson Royal North Shore Hospital, Sydney, NSW 2065, Australia;
Nicole Gilroy Westmead Hospital, Sydney, NSW 2145, Australia;
Andrew R. Lloyd The Kirby Institute, University of New South Wales (UNSW), Sydney, NSW 2052, Australia; (R.A.B.); (M.M.); (A.R.L.)
Pamela Konecny School of Clinical Medicine, University of New South Wales (UNSW), Sydney, NSW 2052, Australia; St. George Hospital, Sydney, NSW 2217, Australia
Francesca Mordant Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; (F.M.); (K.S.) Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC 3000, Australia
Mike Catton Victorian Infectious Diseases Reference Laboratory (VIDRL), The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia; (M.H.B.); (S.N.); (M.C.); (L.C.); (J.D.) Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; (F.M.); (K.S.)
Kanta Subbarao Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; (F.M.); (K.S.) Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC 3000, Australia World Health Organization Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute, Melbourne, VIC 3000, Australia
Leon Caly Victorian Infectious Diseases Reference Laboratory (VIDRL), The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia; (M.H.B.); (S.N.); (M.C.); (L.C.); (J.D.) Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; (F.M.); (K.S.)
Julian Druce Victorian Infectious Diseases Reference Laboratory (VIDRL), The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia; (M.H.B.); (S.N.); (M.C.); (L.C.); (J.D.) Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; (F.M.); (K.S.)
Hans J. Netter Victorian Infectious Diseases Reference Laboratory (VIDRL), The Royal Melbourne Hospital, Melbourne, VIC 3000, Australia; (M.H.B.); (S.N.); (M.C.); (L.C.); (J.D.) Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; (F.M.); (K.S.) School of Science, Royal Melbourne Institute of Technology (RMIT) University, Melbourne, VIC 3001, Australia

Collapse

SARS-COV-2 IgG specific antibodies persistence in recovered COVID-19 individuals and its association with severity and time of illness. New Microbes New Infect 2023;52:101096. [PMID: 36776158 PMCID: PMC9896850 DOI: 10.1016/j.nmni.2023.101096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Revised: 01/28/2023] [Accepted: 02/02/2023] [Indexed: 02/05/2023] Open

Tanaka S, Umezawa J, Yamaji T, Abe SK, Hamada A, Kobayashi O, Ushijima T, Inoue M. SARS-CoV-2 Antibody Response to Symptoms Indicative of COVID-19 in a Non-Infected Population in Japan: a Cross-Sectional Study. Jpn J Infect Dis 2023;76:46-54. [PMID: 36184396 DOI: 10.7883/yoken.jjid.2022.093] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]

Dzananovic B, Williamson M, Nwaigwe C, Routray C. Clinical significance of anti-nucleocapsid-IgG sero-positivity in SARS-CoV-2 infection in hospitalized patients in North Dakota. World J Clin Infect Dis 2022;12:50-60. [DOI: 10.5495/wjcid.v12.i2.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Revised: 08/02/2022] [Accepted: 09/21/2022] [Indexed: 02/05/2023] Open

Abstract

BACKGROUND

During the peak of the coronavirus diseases 2019 (COVID-19) pandemic, clinicians actively studied the utility of various epidemiologic-clinical parameters to determine the prognosis for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Serum IgG antibody level, D-Dimer, C-reactive protein and neutrophil to lymphocyte ratio, etc. were studied to assess their association with the clinical course in hospitalized patients and predict who may be at increased risk for poor clinical outcome. However, the influence of SARS-CoV-2-anti-nucleocapsid-IgG antibody (IgG-N) sero-positivity on the clinical outcome of patients with COVID-19 is largely unknown.

AIM

To study the influence of SARS-CoV-2 anti-nucleocapsid-IgG seropositivity on clinical course and diseases severity in hospitalized COVID-19 patients.

METHODS

We conducted a retrospective study of adults admitted to a tertiary care community hospital in North Dakota with COVID-19. Included patients had severe COVID-19 disease or worse and so required supplemental oxygen on admission. They were serologically tested for SARS-CoV-2-anti-nuceocapsid-IgG (IgG-N). The IgG-N positive group were 26 patients and the IgG-N negative group had 33 patients. The groups received similar treatment for COVID-19 as approved by our healthcare system from Day 1 of admission until discharge or death. Measurable parameters for monitoring the patients’ clinical course included the following: Length of hospitalization (LOS), use of high flow nasal canula (HFNC), use of noninvasive bilevel positive pressure ventilation (BiPAP), admission into the intensive care unit, need for mechanical ventilation (VENT); and the patient outcome/discharge or death. Other variables included were age, gender and body-mass-index, and duration of symptoms before presentation. For each variable, the outcome was modeled as a function of SARS-CoV-2-IgG-N status (positive or negative) using a generalized linear model. For LOS-days, a negative binomial distribution was used as it had a better fit than a Poisson or Gaussian distribution as evidenced by a Pearson chi-square/df value closer to 1.0. All other outcomes utilized a binary logistic regression model.

RESULTS

After a thorough examination of patient data, it was found that admission rates to the Intensive Care Unit, as well as the usage of BiPAP, HFNC and VENT support, in conjunction with patient outcomes, were not significantly different across IgG-N status. However, the LOS variable when assessed by IgG-N status was found to be significant (t value = 2.16, P value = 0.0349). IgG-N negative patients had higher than average LOS in comparison to IgG-N positive patients (15.12 vs 9.35 d). Even when removing the extreme value (an LOS of 158 d), IgG-N negative patients still had slightly higher than average stays (10.66 vs 9.35 d) but the relationship was no longer significant. For patient outcome/death, only age (numerical) was a significant predictor (F value = 4.66, P value = 0.0352). No other variables for any of the outcomes were significant predictors of clinical course or disease severity.

CONCLUSION

Our study demonstrated that IgG-N seroconversion had no significant association with clinical outcomes in hospitalized COVID-19 patients.

Collapse

Zhang Y, Zheng X, Sheng W, Liang H, Zhao Y, Zhu X, Yang R, Zhang Y, Dong X, Li W, Pei F, Ding L, Chang Z, Deng L, Yuan G, Yang Z, Zhu D, Yang X, Wang H. Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants. Vaccines (Basel) 2022;10:vaccines10081208. [PMID: 36016098 PMCID: PMC9413105 DOI: 10.3390/vaccines10081208] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 07/20/2022] [Accepted: 07/26/2022] [Indexed: 11/16/2022] Open

Affiliation(s)

Yuntao Zhang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.) China National Biotec Group Company Limited, Beijing 100024, China
Xiaotong Zheng Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Wang Sheng College of Life Sciences and Biotechnology, Beijing University of Technology, Beijing 100021, China;
Hongyang Liang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Yuxiu Zhao Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Xiujuan Zhu Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Rong Yang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Yadan Zhang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Xiaofei Dong Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Weidong Li Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Fei Pei Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Ling Ding Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Zhen Chang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Li Deng Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Guangying Yuan Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Zhaona Yang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Di Zhu Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Xiaoming Yang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.) China National Biotec Group Company Limited, Beijing 100024, China Correspondence: (X.Y.); (H.W.)
Hui Wang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.) Correspondence: (X.Y.); (H.W.)

Collapse

Takeshita M, Nishina N, Moriyama S, Takahashi Y, Ishii M, Saya H, Kondo Y, Kaneko Y, Suzuki K, Fukunaga K, Takeuchi T. Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. Clin Immunol 2022;238:108999. [PMID: 35398519 PMCID: PMC8988444 DOI: 10.1016/j.clim.2022.108999] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 12/14/2021] [Accepted: 04/04/2022] [Indexed: 01/03/2023]

Štěpánek L, Janošíková M, Štěpánek L, Nakládalová M, Boriková A. The kinetics and predictors of anti-SARS-CoV-2 antibodies up to eight months after symptomatic COVID-19: a Czech cross-sectional study. J Med Virol 2022;94:3731-3738. [PMID: 35419860 PMCID: PMC9088611 DOI: 10.1002/jmv.27784] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 04/06/2022] [Accepted: 04/12/2022] [Indexed: 11/08/2022]

Abstract

The presence of neutralizing SARS‐CoV‐2‐specific antibodies indicates protection against (re)infection, however, the knowledge of their long‐term kinetics is limited. This study analyzed the presence of COVID‐19‐induced antibodies in unvaccinated healthcare workers (HCWs) over the period of 1–8 months post symptom onset (SO) and explored the determinants of persisting immunoglobulin (Ig) seropositivity. Six hundred sixty‐two HCWs were interviewed for anamnestic data and tested for IgG targeting the spike protein (S1 and S2) and IgM targeting the receptor‐binding domain. A Cox regression model was used to explore potential predictors of seropositivity with respect to the time lapse between SO and serology testing. 82.9% and 44.7% of HCWs demonstrated IgG and IgM seropositivity, respectively, with a mean interval of 83 days between SARS‐CoV‐2 detection and serology testing. On average, HCWs reported seven symptoms in the acute phase lasting 20 days. IgG seropositivity rates among HCWs decreased gradually to 80%, 50%, and 35% at 3, 6, and 8 months after SO, while IgM seropositivity fell rapidly to 60%, 15%, and 0% over the same time intervals. The number of symptoms was the only predictor of persisting IgG seropositivity (odds ratio [OR] 1.096, 95% confidence interval [CI] 1.003–1.199, p = 0.043) and symptom duration a predictor of IgM seropositivity (OR 1.011, 95% CI 1.004–1.017, p = 0.002). Infection‐induced anti‐SARS‐CoV‐2 IgG rates drop to a third in seropositive participants over the course of 8 months. Symptom count and duration in the acute phase of COVID‐19 are both relevant to the subsequent kinetics of antibody responses.

60% and 35% of subjects maintain IgG seropositivity 6‐ and 8‐month post COVID‐19.

Characteristics of the acute phase of COVID‐19 are relevant for antibody responses.

The number of symptoms of acute COVID‐19 predicts persisting IgG seropositivity.

Symptom duration predicts persisting IgM seropositivity.

Anamnestic data may serve as simple predictors of seropositivity post COVID‐19.

Collapse

Guo Y, Meng J, Liu C, Chen G, Chi Y, Zheng S, Wang H. How to Deal With Vaccine Breakthrough Infection With SARS-CoV-2 Variants. Front Public Health 2022;10:842303. [PMID: 35372196 PMCID: PMC8965021 DOI: 10.3389/fpubh.2022.842303] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Accepted: 02/08/2022] [Indexed: 01/17/2023] Open

Almeida R, Desormais I, Taton P, Morales E, Reis A, Simba Y. COVID immunity in the Angolan population: Serological study with Abbott COVID-19 IgG/IgM Rapid Test and serological mini VIDAS BIOMERIEUX test. MGM JOURNAL OF MEDICAL SCIENCES 2022. [DOI: 10.4103/mgmj.mgmj_91_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open

Cappuccilli M, Bruno PF, Spazzoli A, Righini M, Flachi M, Semprini S, Grumiro L, Marino MM, Schiavone P, Fabbri E, Fantini M, Buscaroli A, Rigotti A, La Manna G, Sambri V, Mosconi G. Persistence of Antibody Responses to the SARS-CoV-2 in Dialysis Patients and Renal Transplant Recipients Recovered from COVID-19. Pathogens 2021;10:1289. [PMID: 34684237 PMCID: PMC8541005 DOI: 10.3390/pathogens10101289] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 09/27/2021] [Accepted: 10/04/2021] [Indexed: 12/14/2022] Open

Affiliation(s)

Maria Cappuccilli Nephrology, Dialysis and Renal Transplant Unit, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy; (M.C.); (G.L.M.)
Paolo Ferdinando Bruno Nephrology and Dialysis Unit, AUSL Romagna Morgagni-Pierantoni Hospital, 47121 Forlì, Italy; (P.F.B.); (A.S.)
Alessandra Spazzoli Nephrology and Dialysis Unit, AUSL Romagna Morgagni-Pierantoni Hospital, 47121 Forlì, Italy; (P.F.B.); (A.S.)
Matteo Righini Nephrology and Dialysis Unit, AUSL Romagna S. Maria delle Croci Hospital, 48121 Ravenna, Italy; (M.R.); (A.B.)
Marta Flachi Nephrology and Dialysis Unit, AUSL Romagna Infermi Hospital, 47923 Rimini, Italy; (M.F.); (A.R.)
Simona Semprini Unit of Microbiology, AUSL Romagna Laboratory, 47023 Pievesestina, Italy; (S.S.); (L.G.); (M.M.M.); (P.S.); (V.S.)
Laura Grumiro Unit of Microbiology, AUSL Romagna Laboratory, 47023 Pievesestina, Italy; (S.S.); (L.G.); (M.M.M.); (P.S.); (V.S.)
Maria Michela Marino Unit of Microbiology, AUSL Romagna Laboratory, 47023 Pievesestina, Italy; (S.S.); (L.G.); (M.M.M.); (P.S.); (V.S.)
Pasqua Schiavone Unit of Microbiology, AUSL Romagna Laboratory, 47023 Pievesestina, Italy; (S.S.); (L.G.); (M.M.M.); (P.S.); (V.S.)
Elisabetta Fabbri Local Healthcare Authority of Romagna (AUSL Romagna), 48121 Ravenna, Italy; (E.F.); (M.F.)
Michela Fantini Local Healthcare Authority of Romagna (AUSL Romagna), 48121 Ravenna, Italy; (E.F.); (M.F.)
Andrea Buscaroli Nephrology and Dialysis Unit, AUSL Romagna S. Maria delle Croci Hospital, 48121 Ravenna, Italy; (M.R.); (A.B.)
Angelo Rigotti Nephrology and Dialysis Unit, AUSL Romagna Infermi Hospital, 47923 Rimini, Italy; (M.F.); (A.R.)
Gaetano La Manna Nephrology, Dialysis and Renal Transplant Unit, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy; (M.C.); (G.L.M.)
Vittorio Sambri Unit of Microbiology, AUSL Romagna Laboratory, 47023 Pievesestina, Italy; (S.S.); (L.G.); (M.M.M.); (P.S.); (V.S.)
Giovanni Mosconi Nephrology and Dialysis Unit, AUSL Romagna Morgagni-Pierantoni Hospital, 47121 Forlì, Italy; (P.F.B.); (A.S.)

Collapse